Which laboratory tests should be ordered to evaluate Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infection?

Laboratory Testing for EBV and CMV

For suspected acute EBV infection (mononucleosis), start with a heterophile antibody test (Monospot); if negative, order EBV VCA IgM, VCA IgG, and EBNA antibodies. For suspected acute CMV infection in immunocompetent patients, order CMV IgM and IgG antibodies as the first-line test. 1

EBV Testing Algorithm

Initial Testing for Suspected Mononucleosis

• Heterophile antibody test (Monospot) on serum
  • Becomes detectable between days 6-10 after symptom onset
  • Peaks at weeks 2-3 of illness
  • Important caveat: False-negatives occur in ~10% of patients, especially common in children <10 years old 1
  • False-positives can occur with leukemia, pancreatic carcinoma, viral hepatitis, or CMV infection 1

When Monospot is Negative

Order EBV-specific antibody panel 1:

• VCA IgM - indicates recent/acute infection
• VCA IgG - appears early, persists for life
• EBNA antibodies - critical for timing the infection

Interpretation pattern for acute EBV infection: VCA IgM present (with or without VCA IgG) + EBNA antibodies absent 1

Key timing: EBNA antibodies develop 1-2+ months after primary infection, so their presence indicates infection occurred >6 weeks ago and EBV is unlikely the current cause 1

Special Populations - Immunocompromised Patients

For transplant recipients or immunocompromised patients, use quantitative EBV DNA PCR (viral load) on whole blood, peripheral blood lymphocytes, or plasma 1:

• Monitor for lymphoproliferative disease risk
• Viral load increases precede clinical disease
• Specimen: EDTA tube, room temperature, <2 hours transport time 1

CMV Testing Algorithm

Immunocompetent Patients

CMV-specific antibodies are the first-line test 1:

• CMV IgM - indicates recent/acute infection
  • Critical caveat: False-positive CMV IgM can occur with EBV infection or other immune activation 1
• CMV IgG alone - indicates past exposure only

Immunocompromised Patients (Transplant Recipients)

Use CMV DNA quantitative PCR (viral load) by nucleic acid amplification test (NAAT) 1:

• Used for preemptive therapy decisions
• Monitoring during treatment
• Diagnosing CMV disease
• Preferred over antigenemia testing (pp65), which is being phased out 1

Specimen options 1:

• Plasma (preferred for viral load)
• Whole blood
• CSF, urine, tissues, respiratory specimens for qualitative detection
• Sterile container, room temperature, <2 hours transport time

Common Pitfalls to Avoid

1. Cross-reactivity: CMV infection can cause false-positive EBV IgM results, and vice versa 1, 2. When one virus is suspected, consider testing for both to clarify the diagnosis.

2. Timing matters: Ordering EBNA antibodies alone without VCA antibodies is insufficient - you need the complete panel to distinguish acute from past infection 1

3. Age considerations: Heterophile antibody tests have high false-negative rates in children <10 years, so proceed directly to EBV-specific antibodies in this age group 1

4. Immunocompromised patients: Antibody testing is unreliable after transplantation; always use PCR-based viral load testing instead 1

5. Don't rely on culture: CMV culture is labor-intensive (up to 14 days), has poor sensitivity, and is largely obsolete except for congenital CMV diagnosis from urine in some institutions 1